Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $4.4 million.

  • Spyre Therapeutics' Change in Accured Expenses fell 40.12% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 1056.27%. This contributed to the annual value of $14.6 million for FY2024, which is 398.69% up from last year.
  • Per Spyre Therapeutics' latest filing, its Change in Accured Expenses stood at $4.4 million for Q3 2025, which was up 291.70% from -$2.3 million recorded in Q2 2025.
  • Spyre Therapeutics' Change in Accured Expenses' 5-year high stood at $14.9 million during Q4 2024, with a 5-year trough of -$15.8 million in Q2 2024.
  • For the 3-year period, Spyre Therapeutics' Change in Accured Expenses averaged around $530,000, with its median value being -$891,000 (2023).
  • Examining YoY changes over the last 5 years, Spyre Therapeutics' Change in Accured Expenses showed a top increase of 1,768.46% in 2024 and a maximum decrease of 849.00% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Change in Accured Expenses (Quarterly) stood at $455,000 in 2021, then declined by 1.10% to $450,000 in 2022, then plummeted by 298.00% to -$891,000 in 2023, then skyrocketed by 1,768.46% to $14.9 million in 2024, then tumbled by 40.12% to $4.4 million in 2025.
  • Its Change in Accured Expenses stands at $4.4 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$6.0 million for Q1 2025.